Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease
Ontology highlight
ABSTRACT: The ETCTN 10026 study tested decitabine and ipilimumab for transplant-naive advanced myelodysplastic syndrome/acute myeloid leukemia and relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. Using single cell RNA sequencing, determinants of response (higher T/NK to myeloid cell ratio in responders) and resistance (insufficient clearance of AML clones) were identified and pharmacodynamics of decitabine (cytoreduction) and ipilimumab (increase in regulatory T cells) characterized.
ORGANISM(S): Homo sapiens
PROVIDER: GSE223844 | GEO | 2023/10/31
REPOSITORIES: GEO
ACCESS DATA